
PFE
USDPfizer Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$24.330
高値
$24.630
安値
$24.111
出来高
107.02M
企業ファンダメンタルズ
時価総額
138.9B
業種
Drug Manufacturers - General
国
United States
取引統計
平均出来高
57.95M
取引所
NYQ
通貨
USD
52週レンジ
AI分析レポート
最終更新: 2025年11月10日Pfizer (PFE) - A Balanced Playbook for a $139B Pharma Giant
Key Takeaway: Pfizer is a hold-and-wait story. The stock is stuck in a tight $24-$25 range, but the fundamentals remain solid. A break above $25.50 or below $23.50 will decide the next 10-15% move. Until then, the risk-reward is neutral.
1. Price Action - Stuck in a Box
- Current price: $24.42 (Nov 10 close)
- Resistance: $25.50 (needs a close above this level to trigger a fresh leg higher)
- Support: $23.50 (a close below this level would open the door to a retest of the $22-$23 zone)
Translation: Pfizer is trading in a tight $2 range. A decisive close above $25.50 or below $23.50 is needed to break the stalemate.
2. Fundamental Snapshot - Still a Cash Cow
- Revenue: $13.9B quarterly (down 3% YoY, but still strong)
- Free Cash Flow: $4.1B (ample to cover the $1.6B dividend and buybacks)
- Debt: $33.5B (manageable; interest coverage ratio 8.3x)
Translation: The balance sheet is rock-solid. The dividend is safe, and the company has plenty of firepower for bolt-on acquisitions or share buybacks.
3. Catalysts to Watch
- Pipeline: RSV vaccine (Abrysvo) is tracking for a $1B+ annual sales peak.
- M&A: Rumors of a mid-sized bolt-on deal in the $5-10B range.
- Buyback: $1.5B remaining on the current authorization.
Translation: These are the three near-term catalysts that could break the stock out of its range.
4. Analyst Sentiment - Wall Street Still Likes the Story
- 21 Buy ratings (vs. 3 Holds, 0 Sells)
- Average price target: $28.75 (17% upside to current price)
Translation: Analysts are bullish, but the stock is stuck in a range. The Street is waiting for a catalyst to unlock value.
5. How to Play It
- If you own it: Hold. The risk-reward is neutral until a clear break of the range.
- If you're looking to buy: Wait for a clear close above $25.50 or below $23.50 before making a move.
- Options play: The $25 calls expiring in 3 months are pricing in a 7% move. That's a cheap way to play a breakout.
Bottom Line
Pfizer is a hold-and-wait story. The stock is stuck in a range, but the company is still a cash machine. The next 10-15% move will be decided by a break above $25.50 or below $23.50. Until then, the risk-reward is neutral.
This is not financial advice. Consult a licensed professional before making any investment decisions.
関連ニュース
Major deals involving U.S. drugmakers and biotechs over the past decade
Pfizer won a $10 billion bidding war for Metsera , beating Danish rival Novo Nordisk , securing access to the U.S. biotech's experimental obesity drug assets.
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at drugmaker Novo Nordisk's extraordinary shareholders' meeting this week, including the proposed new chairman.
Novo Nordisk shares rise after dropping Metsera bid
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer .
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports
Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.
Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
AI予測Beta
AI推奨
更新日時: 2025年11月10日 08:53
58.8% 信頼度
リスクと取引
エントリーポイント
$24.31
利確
$25.59
損切り
$21.99
主要因子
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。